Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers
Solid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01746/full |
| _version_ | 1819085918013751296 |
|---|---|
| author | Roghaye Arezumand Abbas Alibakhshi Javad Ranjbari Ali Ramazani Serge Muyldermans |
| author_facet | Roghaye Arezumand Abbas Alibakhshi Javad Ranjbari Ali Ramazani Serge Muyldermans |
| author_sort | Roghaye Arezumand |
| collection | DOAJ |
| description | Solid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and large size of mAbs seem to narrow the therapeutic applications. To improve the performance of cancer therapeutics, including those blocking tumor angiogenesis, attractive strategies such as miniaturization of the antibodies have been introduced. Nanobodies (Nbs), small single-domain antigen-binding antibody fragments, are becoming promising therapeutic and diagnostic proteins in oncology due to their favorable unique structural and functional properties. This review focuses on the potential and state of the art of Nbs to inhibit the angiogenic process for therapy and the use of labeled Nbs for non-invasive in vivo imaging of the tumors. |
| first_indexed | 2024-12-21T21:11:59Z |
| format | Article |
| id | doaj.art-af233850aeca42c08055051671cabc3c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T21:11:59Z |
| publishDate | 2017-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-af233850aeca42c08055051671cabc3c2022-12-21T18:50:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-12-01810.3389/fimmu.2017.01746292547Nanobodies As Novel Agents for Targeting Angiogenesis in Solid CancersRoghaye Arezumand0Abbas Alibakhshi1Javad Ranjbari2Ali Ramazani3Serge Muyldermans4Department of Biotechnology and Molecular Science, School of Medicine, North Khorasan University of Medical Sciences, Bojnourd, IranDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IranCancer Gene Therapy Research Center, Zanjan University of Medical Sciences, Zanjan, IranCellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, BelgiumSolid cancers are dependent on angiogenesis for sustenance. The FDA approval of Bevacizumab in 2004 inspired many scientists to develop more inhibitors of angiogenesis. Although several monoclonal antibodies (mAbs) are being administered to successfully combat various pathologies, the complexity and large size of mAbs seem to narrow the therapeutic applications. To improve the performance of cancer therapeutics, including those blocking tumor angiogenesis, attractive strategies such as miniaturization of the antibodies have been introduced. Nanobodies (Nbs), small single-domain antigen-binding antibody fragments, are becoming promising therapeutic and diagnostic proteins in oncology due to their favorable unique structural and functional properties. This review focuses on the potential and state of the art of Nbs to inhibit the angiogenic process for therapy and the use of labeled Nbs for non-invasive in vivo imaging of the tumors.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01746/fullangiogenesisnanobodymonoclonal antibodycancer therapyvascular endothelial growth factor family |
| spellingShingle | Roghaye Arezumand Abbas Alibakhshi Javad Ranjbari Ali Ramazani Serge Muyldermans Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers Frontiers in Immunology angiogenesis nanobody monoclonal antibody cancer therapy vascular endothelial growth factor family |
| title | Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers |
| title_full | Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers |
| title_fullStr | Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers |
| title_full_unstemmed | Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers |
| title_short | Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers |
| title_sort | nanobodies as novel agents for targeting angiogenesis in solid cancers |
| topic | angiogenesis nanobody monoclonal antibody cancer therapy vascular endothelial growth factor family |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01746/full |
| work_keys_str_mv | AT roghayearezumand nanobodiesasnovelagentsfortargetingangiogenesisinsolidcancers AT abbasalibakhshi nanobodiesasnovelagentsfortargetingangiogenesisinsolidcancers AT javadranjbari nanobodiesasnovelagentsfortargetingangiogenesisinsolidcancers AT aliramazani nanobodiesasnovelagentsfortargetingangiogenesisinsolidcancers AT sergemuyldermans nanobodiesasnovelagentsfortargetingangiogenesisinsolidcancers |